The single VSV‐GP and DCVacc, as well as the DCVacc/VSV‐GP combination therapy significantly elevated the absolute number of CD45+ infiltrating immune cells per gram tumor compared to the PBS control group and a significant increase of CD45+ immune cells upon DCVacc/VSV‐GP treatment compared to DCVacc alone was seen (Fig. 3a). This evidence concerns the gene PTPRC and neoplasm.